Identifying novel biomarkers associated with bladder cancer treatment outcomes
Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1114203/full |
| _version_ | 1797857826829238272 |
|---|---|
| author | Peris R. Castaneda Dan Theodorescu Dan Theodorescu Charles J. Rosser Charles J. Rosser Michael Ahdoot |
| author_facet | Peris R. Castaneda Dan Theodorescu Dan Theodorescu Charles J. Rosser Charles J. Rosser Michael Ahdoot |
| author_sort | Peris R. Castaneda |
| collection | DOAJ |
| description | Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms “biomarker,” “bladder cancer,” and the respective treatment discussed (i.e., “neoadjuvant” or “BCG”). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection. |
| first_indexed | 2024-04-09T21:04:08Z |
| format | Article |
| id | doaj.art-746f7b6388b4401581657b073d1774c7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T21:04:08Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-746f7b6388b4401581657b073d1774c72023-03-29T05:13:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11142031114203Identifying novel biomarkers associated with bladder cancer treatment outcomesPeris R. Castaneda0Dan Theodorescu1Dan Theodorescu2Charles J. Rosser3Charles J. Rosser4Michael Ahdoot5Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, United StatesDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, United StatesSamuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, United StatesDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, United StatesSamuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, United StatesDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, United StatesBladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms “biomarker,” “bladder cancer,” and the respective treatment discussed (i.e., “neoadjuvant” or “BCG”). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection.https://www.frontiersin.org/articles/10.3389/fonc.2023.1114203/fullbiomarkerbladder cancergenetic testingtreatmenttargeted therapy |
| spellingShingle | Peris R. Castaneda Dan Theodorescu Dan Theodorescu Charles J. Rosser Charles J. Rosser Michael Ahdoot Identifying novel biomarkers associated with bladder cancer treatment outcomes Frontiers in Oncology biomarker bladder cancer genetic testing treatment targeted therapy |
| title | Identifying novel biomarkers associated with bladder cancer treatment outcomes |
| title_full | Identifying novel biomarkers associated with bladder cancer treatment outcomes |
| title_fullStr | Identifying novel biomarkers associated with bladder cancer treatment outcomes |
| title_full_unstemmed | Identifying novel biomarkers associated with bladder cancer treatment outcomes |
| title_short | Identifying novel biomarkers associated with bladder cancer treatment outcomes |
| title_sort | identifying novel biomarkers associated with bladder cancer treatment outcomes |
| topic | biomarker bladder cancer genetic testing treatment targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1114203/full |
| work_keys_str_mv | AT perisrcastaneda identifyingnovelbiomarkersassociatedwithbladdercancertreatmentoutcomes AT dantheodorescu identifyingnovelbiomarkersassociatedwithbladdercancertreatmentoutcomes AT dantheodorescu identifyingnovelbiomarkersassociatedwithbladdercancertreatmentoutcomes AT charlesjrosser identifyingnovelbiomarkersassociatedwithbladdercancertreatmentoutcomes AT charlesjrosser identifyingnovelbiomarkersassociatedwithbladdercancertreatmentoutcomes AT michaelahdoot identifyingnovelbiomarkersassociatedwithbladdercancertreatmentoutcomes |